Glycogen storage disease type I epidemiology and demographics
Glycogen storage disease type I Microchapters |
Differentiating Glycogen storage disease type I from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Glycogen storage disease type I epidemiology and demographics On the Web |
American Roentgen Ray Society Images of Glycogen storage disease type I epidemiology and demographics |
FDA on Glycogen storage disease type I epidemiology and demographics |
CDC on Glycogen storage disease type I epidemiology and demographics |
Glycogen storage disease type I epidemiology and demographics in the news |
Blogs on Glycogen storage disease type I epidemiology and demographics |
Directions to Hospitals Treating Glycogen storage disease type I |
Risk calculators and risk factors for Glycogen storage disease type I epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Epidemiology and Demographics
Like most serious enzyme deficiencies, GSD Ia is inherited as an autosomal recessive disease. Heterozygote carriers (parents) are asymptomatic. As for other autosomal recessive diseases, the recurrence risk for each subsequent child of the same parents is 25%. Prenatal diagnosis has been made by fetal liver biopsy at 18-22 weeks of gestation, but no fetal treatment has been proposed. Prenatal diagnosis is possible with fetal DNA obtained by chorionic villus sampling when a fetus is known to be at risk.
GSD Ia has an incidence in the American population of approximately 1 in 100,000 to 200,000 births. None of the glycogenoses are currently detected by standard or extended newborn screening.